Abstract
Chemotherapy for the treatment of advanced or metastatic colon cancer, utilizing agents such as 5-fluorouracil (5-FU) and irinotecan (CPT-11), produce a 5-year survival of about 10%. Thus, the identification of new, effective, therapeutic regimens to treat this disease remains critically important. To this end, selected antiangiogenic agents, compounds that inhibit neovascularization, have been shown to produce a modest tumor growth-inhibitory effect with little systemic toxicity. Thus these agents are attractive candidates for use with conventional chemotherapeutic agents to treat this disease. To evaluate this approach, experiments were undertaken to assess the cytotoxic and antineoplastic activity of CPT-11 and the antiangiogenic agent thrombospondin-1 (TSP-1) in the HT-29 model of human colon cancer. These agents were chosen since CPT-11 is a camptothecin analogue efficacious in the treatment of colon cancer and TSP-1 is a human glycoprotein that possess antiangiogenic activity. As expected, in vitro studies revealed that a 5-day exposure to TSP-1 at concentrations up to 130 μg/ml was not cytotoxic alone and did not affect the cytotoxicity of CPT-11, or of its active metabolite SN38, in HT-29 cells. Similarly, in human umbilical vein endothelial cells, TSP-1 alone induced only a slight cell growth-inhibitory effect and did not significantly increase the cytotoxicity of either CPT-11 or SN38. The antineoplastic activities of TSP-1 and CPT-11 were assessed in athymic (nude) female mice bearing advanced subcutaneous xenografts of HT-29 cells. Mice received TSP-1 alone (5–40 mg/kg per day) intraperitoneally (i.p.), CPT-11 alone (100–300 mg/kg, i.p.), TSP-1 (10 mg/kg per day) plus CPT-11 (125 mg/kg), or TSP-1 (20 mg/kg per day) plus CPT-11 (150 mg/kg). TSP-1 was injected daily (Monday through Friday) for 4 weeks (20 injections in total) whereas CPT-11 was administered once weekly on days 0, 7, 14 and 21. By day 28, treatment with TSP-1 alone (5, 10 or 20 mg/kg per day) induced a dose-dependent inhibition of xenograft growth. Further, treatment with 10 or 20 mg/kg per day resulted in an average treated tumor size/control tumor size (T/C) on day 28 of 0.68 (range 0.64–0.71) or 0.58 (range 0.54–0.60), respectively. CPT-11 at all doses significantly inhibited tumor growth with an average T/C value of 0.21 (range 0.15–0.27). However, the 250 and 300 mg/kg regimens induced significant toxicity and mortality. When TSP-1 was combined with CPT-11, a significant (P≤0.05) inhibition of tumor growth also was observed (T/C ≤0.17, range 0.11–0.20). Importantly, this enhanced tumor growth inhibition was obtained without significant toxicity. The therapeutic implications of these findings are discussed.
Similar content being viewed by others
Abbreviations
- bFGF:
-
Basic fibroblast growth factor
- CPT-11:
-
Irinotecan
- 5-FU:
-
5-Fluorouracil
- HUVEC:
-
Human umbilical vein endothelial cells
- i.p.:
-
Intraperitoneally
- SN38:
-
7-Ethyl-10-hydroxy camptothecin
- T/C:
-
Treated tumor size/control tumor size
- TSP-1:
-
Thrombospondin-1
- VEGF:
-
Vascular endothelial growth factor
References
Allegrini G, Goulette FA, Darnowski JW, Calabresi P (2000) The angiogenesis inhibitor thrombospondin-1 plus irinotecan significantly inhibit tumor growth in human colon tumor bearing nude mice. Proc Am Assoc Cancer Res 41:813
Boehm T, Folkman J, Browder T, O’Reilly SM (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404
Browne PV, Mosher DF, Steimberg MH, Hebbel RP (1996) Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol 51:296
Brunetti I, Falcone A, Calabresi P, Goulette FA, Darnowski JW (1990) 5-Fluorouracil enhances azidothymidine cytotoxicity. In vitro, in vivo and biochemical studies. Cancer Res 50:4026
Chodak GW, Hospelhorn V, Judge SM, Mayforth R, Koeppen H, Sasse J (1988) Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res 48:2083
Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effect of multiple drugs and enzyme inhibitors. In: Weber G (ed) Advances in enzyme regulation. Pergamon Press, New York, p 27
Cohen AM, Minsky BD, Schilsky RL (1997) Cancer of the colon. In: DeVita VT, Hellman S, Rosemberg SA (eds) Cancer. Principles and practice of oncology, 5th edn. Lippincott-Raven, Philadelphia, p 1144
Darnowski JW, Sawyer RC, Stolfi RL, Martin DS, LauCam C (1985) Decreased host toxicity in vivo during chronic treatment with fluorouracil. Cancer Chemother Pharmacol 14:63
Darnowski JW, Davol PA, Goulette FA (1997) Human recombinant interferon alpha-2a plus 3′-azido-3′-deoxythymidine. Synergistic growth inhibition with evidence of impaired DNA repair in human colon adenocarcinoma cells. Biochem Pharmacol 53:571
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandis K, Iveson T, Carmichael J, Alakl M, Gruia G, Award L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355:1041
Elion GB, Singer S, Hitchings GH (1954) Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of chemically related antimetabolites. J Biol Chem 208:477
Fisher LD, van Belle G (1993) One- and two-sample inference. In: Camoise RA (ed) Biostatistics, a methodology for the health sciences. Wiley, New York, p 138
Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4
Fong T, Annie T, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McManon G (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99
Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JT, Levi F (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10:663
Good DJ, Polverini PJ, Rastinejad F, Le BM, Lemons RS, Frazier WA, Bouck NP (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 87:6624
Grem JL (1997) Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin. Semin Oncol 24:S18
Guo N, Krutzsch HC, Inman JK, Roberts DD (1997) Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57:1735
Herbst RS, Takeuchi H, Teicher BA (1998) Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother Pharmacol 41:497
Hsiang YH, Liu FL (1988) Identification of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722
Iruela-Arispe M, Bornestein P, Sage H (1991) Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci U S A 88:5026
Kakeji Y, Teicher BA (1997) Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 15:39
Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun K, Folkman J, Hanahan ND (1991) Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66:1095
Konno H, Tanaka T, Kanai T, Maruyama K, Nakamura S, Baba S (1996) Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential. Cancer 77:1736
Lahav J (1988) Thrombospondin-1 inhibits adhesion of endothelial cells. Exp Cell Res 177:199
Larkin M (1999) Low-dose thalidomide seems to be effective in multiple myeloma. Lancet 354:925
Lavelle F, Bissery MC, Andre S, Roquet F, Riou JF (1996) Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol 23:11
Liu B, Liao J, Rao X, Kushner S, Chung CD, Chang DD, Shuai K (1998) Inhibition of Stat-mediated gene activation of PIAS 1. Proc Natl Acad Sci U S A 95:10626
Nanus DM, Schimitz-Drager BJ, Motzer RJ, Lee AC, Vlamis V, CordonCardo C, Albino AP, Reuter VE (1993) Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 85:1597
Narazaki M, Fujimoto M, Matzumoto T, Morita Y, Saito H, Kajita T, Yoshizaki K, Naka T, Kishimoto T (1998) Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin-6 signaling. Proc Natl Acad Sci U S A 95:13130
Nathan FE, Hernandez E, Dunton CJ, Treat J, Switalska HI, Joseph RR, Tuszynski P (1994) Plasma thrombospondin levels in patients with gynecologic malignancies. Cancer 73:2853
Nicholson SE, Hilton DJ (1998) The SOCS proteins: a new family of negative regulators of signal transduction. J Leukoc Biol 63:665
Offodile R, Walton T, Lee M, Stiles A, Nguyen M (1999) Regression of metastatic breast cancer in a patient treated with the anti-angiogenic drug TNP-470. Tumori 85:51
O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WL, Cao Y, Sage EH, Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315
Pantazis P, Kolielski A, Rodriquez R, Petry E, Wani M, Wall M, Giovanella BC (1994) Therapeutic efficacy of camptothecin derivatives against human malignant melanoma xenografts. Melanoma Res 4:5
Pommier Y (1996) Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin Oncol 23:3
Roberts DD (1996) Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J 10:1183
Rosemurgy A, Harris J, Langleben A, Casper E, GoodeS, Rasmussen H (1999) Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol 22:247
Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 343:905
Streit M, Velasco P, Brown LF, Skobe M, Richard L, Riccardi L, Lawler J, Detmar M (1999) Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 155:441
The American Cancer Society (2002) Colorectal cancer and early detection. Cancer Facts and Figures 2002. American Cancer Society, Atlanta
Tosi P, Calabresi P, Goulette F, Renaud C, Darnowski JW (1992) 3′-Azido-3′-deoxythymidine antineoplastic activity is enhanced by methotrexate in vitro and in vivo. Cancer Res 52:4069
Tuszynski GP, Gasic TB, Rothman VL, Knudsen KA, Gasic GJ (1987) Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res 47:4130
Tuszynski GP, Smith M, Rothman L, Capuzzi DM, Joseph RR, Katz J, Besa EC, Treat J, Switalska HI (1992) Thrombospondin levels in patients with malignancy. Thromb Haemost 67:607
Vanhoefer U, Harstrick A, Kohne CH, Achterrath W, Rustum YM, Seeber S, Wilke H (1999) Phase I study of a weekly schedule of irinotecan: high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 17:907
Volpert ON, Lawler J, Bouck NP (1998) A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci U S A 95:6343
Author information
Authors and Affiliations
Additional information
This work was supported by the TJ Martell Foundation and Rhode Island Hospital.
Rights and permissions
About this article
Cite this article
Allegrini, G., Goulette, F.A., Darnowski, J.W. et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol 53, 261–266 (2004). https://doi.org/10.1007/s00280-003-0712-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-003-0712-y